A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 5, 2019

Primary Completion Date

April 15, 2020

Study Completion Date

April 15, 2020

Conditions
Adenoid Cystic Carcinoma
Interventions
DRUG

Tretinoin

ATRA control normal cell growth, cell differentiation (the normal process of making cell different from each other), and cell death during embryonic development and in certain tissues later in life. Retinoids effects on the cells are controlled by receptors on the nucleus of each cell (nuclear receptors)

Trial Locations (2)

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

The V Foundation

OTHER

collaborator

Adenoid Cystic Carcinoma Research Foundation

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT03999684 - A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma | Biotech Hunter | Biotech Hunter